Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.71 | 0.47 | -0.09 | -0.54 |
| FCF Yield | -30.77% | -15.08% | -14.58% | -2.84% |
| EV / EBITDA | -2.24 | -5.13 | -5.09 | -31.93 |
| Quality | ||||
| ROIC | -48.55% | -42.79% | -33.19% | -21.88% |
| Gross Margin | 82.23% | 75.26% | 85.47% | 79.15% |
| Cash Conversion Ratio | 0.67 | 0.82 | 0.70 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.55% | 3.15% | -3.50% | -8.47% |
| Free Cash Flow Growth | 13.09% | -4.19% | -64.72% | -344.48% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | 0.22 | 0.87 | 0.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.11 | 0.00 |
| Cash Conversion Cycle | -464.03 | 63.79 | -3,564.42 | -488.87 |